Company intelligence / Profile preview

Rainier Therapeutics

San Ramon, California, United Statesbioclinpharm.com ↗

Ownership: Private
Development stage: Other

Overview

BioClin’s lead asset was B-701 (later called vofatamab), a first-in-class human monoclonal antibody targeting FGFR3. It advanced through Phase 1b and Phase 2 studies in metastatic urothelial carcinoma/bladder cancer—both as monotherapy and in combination with docetaxel or immunotherapies like atezolizumab and pembrolizumab. Early results showed promise especially for patients with FGFR3 mutations or overexpression. The company also explored preclinical work on achondroplasia.

Therapeutic areas: Rare DiseasesOncology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Drug pipeline

1 asset

vofatamab

Partnerships

Clinical collaborations using Roche’s atezolizumabClinical collaborations using Merck’s pembrolizumab

Beyond the preview

Go deeper on Rainier Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rainier Therapeutics.

Explore the full profile